Who May Be at Risk for Tysabri-Related PML?
From General Health Awareness to Occupational Risk Assessment
If you or a loved one is taking Tysabri and experiencing new neurological symptoms such as confusion, vision changes, or difficulty speaking, it is critical to recognize these as potential signs of progressive multifocal leukoencephalopathy (PML). Over the past two decades, the medical community has built a substantial body of research on the link between Tysabri and PML, including the typical timeline of onset and risk factors. This page outlines the key symptoms to watch for and what the science says about who may be most at risk.
Tysabri and PML: A Documented Risk
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for moderately to severely active Crohn's disease in adults who have not responded adequately to other treatments. The prescribing information for Tysabri carries a boxed warning stating that the drug increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised patients and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three established risk factors for developing PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk for developing PML. Healthcare professionals are instructed to consider these factors in the context of expected benefit when initiating and continuing treatment with Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to manage the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Clinical Presentation and Diagnostic Challenges
Clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, balance disorder, cognitive impairment, memory loss, and visual changes. The FDA Adverse Event Reporting System (FAERS) database lists adverse events most frequently associated with Tysabri, including fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), asthenia (7,852 reports), balance disorder (5,621 reports), hypoesthesia (5,343 reports), muscular weakness (4,535 reports), cognitive disorder (3,478 reports), and mobility decreased (3,769 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). These symptoms overlap with both multiple sclerosis progression and PML, making early diagnosis challenging. The mechanistic pathway linking Tysabri to PML involves the drug's action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrin on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JCV in the brain. Under normal conditions, JCV is controlled by the immune system; however, when immune cell trafficking is blocked by Tysabri, latent JCV can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML.
Legal Considerations and Statute of Limitations in Illinois
For patients who develop PML after Tysabri exposure, the timeline between drug initiation and documented harm can vary. The boxed warning notes that risk increases with longer treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML has been reported in patients treated for shorter periods, especially if they have additional risk factors such as prior immunosuppressant use or positive anti-JCV antibody status. The prescribing information instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). From a legal perspective, affected patients in Illinois may have questions about the adequacy of warnings provided by the manufacturer regarding the risk of PML. The boxed warning explicitly states that Tysabri increases the risk of PML and identifies known risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, legal considerations may include whether these warnings were sufficiently communicated to prescribing physicians and patients, whether the TOUCH program adequately mitigated risk, and whether the manufacturer failed to update warnings as new risk information emerged. The statute of limitations for product liability claims in Illinois generally requires filing within two years from the date the injury was discovered or should have been discovered. For PML, this discovery date may be when a patient receives a confirmed diagnosis or when symptoms first manifest and are linked to Tysabri. Given the latency period between Tysabri exposure and PML onset, patients should consult with an attorney promptly to determine applicable deadlines.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri-related PML claims in Illinois?
In Illinois, the statute of limitations for product liability claims generally requires filing within two years from the date the injury was discovered or should have been discovered. For PML, this discovery date may be when a patient receives a confirmed diagnosis or when symptoms first manifest and are linked to Tysabri. Given the latency period between Tysabri exposure and PML onset, it is crucial to consult with an attorney promptly to determine applicable deadlines.
What are the risk factors for developing PML from Tysabri?
Three established risk factors for developing PML in Tysabri-treated patients are: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants. Patients who are anti-JCV antibody positive have a higher risk for developing PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.